Patents Assigned to Etern Biopharma (Shanghai) Co., Ltd.
  • METHODS FOR MODULATING A SRC-1 CONDENSATE
    Publication number: 20240125768
    Abstract: Provided are methods for modulating a SRC-1 condensate to regulate transcription of one or more genes, methods of treating diseases and conditions using SRC-1 inhibitors, and methods for screening of agents that modulate SRC-1 condensate.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 18, 2024
    Applicant: ETERN BIOPHARMA ( SHANGHAI)CO, LTD.
    Inventors: Guangya ZHU, Jingjing XIE, Jidong ZHU, Xin GUO, Hao HE
  • Spiro aromatic ring compound and application thereof
    Patent number: 11685748
    Abstract: Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: June 27, 2023
    Assignee: ETERN BIOPHARMA (SHANGHAI) CO., LTD.
    Inventors: Qiangang Zheng, Ming Xu, Qinglong Zeng, Jing Li, Hao Zhuge
  • Spiro aromatic ring compound and application thereof
    Patent number: 10844079
    Abstract: Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 24, 2020
    Assignee: Etern Biopharma (Shanghai) Co., Ltd.
    Inventors: Qiangang Zheng, Ming Xu, Qinglong Zeng, Jing Li, Hao Zhuge